P1565: MITAPIVAT IMPROVES INEFFECTIVE ERYTHROPOIESIS AND REDUCES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY

P1565: MITAPIVAT IMPROVES INEFFECTIVE ERYTHROPOIESIS AND REDUCES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY

Bibliographic Details
Main Authors:	E. J. van Beers, H. Al-Samkari, R. F. Grace, W. Barcellini, A. Glenthøj, M. P. Judge, P. A. Kosinski, R. Xu, V. Beynon, B. McGee, J. B. Porter, K. H. M. Kuo
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000849116.94935.15

Similar Items

P1497: MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
by: Eduard van Beers, et al.
Published: (2023-08-01)

Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment
by: Hanny Al-Samkari, et al.
Published: (2023-09-01)

P1545: DURABILITY OF HEMOGLOBIN RESPONSE AND REDUCTION IN TRANSFUSION BURDEN IS MAINTAINED OVER TIME IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT IN A LONG-TERM EXTENSION STUDY
by: R. F. Grace, et al.
Published: (2022-06-01)

P1548: LONG-TERM TREATMENT WITH ORAL MITAPIVAT IS ASSOCIATED WITH NORMALIZATION OF HEMOGLOBIN LEVELS IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
by: W. Barcellini, et al.
Published: (2022-06-01)

P1735: IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN MITAPIVAT-TREATED PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A DESCRIPTIVE ANALYSIS FROM THE PHASE 3 ACTIVATE TRIAL
by: K. H. Kuo, et al.
Published: (2022-06-01)

P1544: BONE MINERAL DENSITY REMAINS STABLE IN PYRUVATE KINASE DEFICIENCY PATIENTS RECEIVING LONG-TERM TREATMENT WITH MITAPIVAT
by: H. Al-Samkari, et al.
Published: (2022-06-01)

P1477: MITAPIVAT EFFICACY IN ADULTS WITH PYRUVATE KINASE DEFICIENCY AND BASELINE HEMOGLOBIN LEVELS >10 G/DL
by: Rachael F. Grace, et al.
Published: (2023-08-01)

P1546: ACTIVATE-KIDST: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
by: R. F. Grace, et al.
Published: (2022-06-01)

P1547: ACTIVATE-KIDS: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
by: R. F. Grace, et al.
Published: (2022-06-01)

Iron Loading and Overloading due to Ineffective Erythropoiesis
by: Toshihiko Tanno, et al.
Published: (2010-01-01)

P1473: CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT – A SUB-ANALYSIS OF THE ACTIVATE TRIAL
by: Hanny Al-Samkari, et al.
Published: (2023-08-01)

Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice
by: Alessandro Mattè, et al.
Published: (2023-02-01)

𝛽-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload
by: Luca Melchiori, et al.
Published: (2010-01-01)

S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
by: K Kuo, et al.
Published: (2022-01-01)

P1522: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
by: K. H. M. Kuo, et al.
Published: (2022-06-01)

P1543: MITAPIVAT DECREASES THE NEED FOR TRANSFUSIONS SECONDARY TO POORLY TOLERATED ANEMIA AND ACUTE EVENTS COMPARED TO PLACEBO IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
by: H. Al-Samkari, et al.
Published: (2022-06-01)

Increasing serum transferrin to reduce tissue iron overload due to ineffective erythropoiesis
by: Emanuela Tolosano
Published: (2015-05-01)

Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice
by: Wenbin An, et al.
Published: (2023-12-01)

Mitapivat: New dawn in pyruvate kinase deficiency and beyond
by: Ritika Khurana, et al.
Published: (2024-06-01)

Ineffective Erythropoiesis in β-Thalassemia
by: Jean-Antoine Ribeil, et al.
Published: (2013-01-01)

Dyserythropoiesis and ineffective erythropoiesis in Plasmodium vivax malaria.
by: Wickramasinghe, SN, et al.
Published: (1989)

Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease
by: Myrthe J. vanDijk, et al.
Published: (2024-06-01)

P1562: CHARACTERIZING IRON OVERLOAD BY AGE IN PATIENTS DIAGNOSED WITH PYRUVATE KINASE DEFICIENCY – A DESCRIPTIVE ANALYSIS FROM THE PEAK REGISTRY
by: P. Bianchi, et al.
Published: (2022-06-01)

The interactions between ineffective erythropoiesis and ferroptosis in β-thalassemia
by: Siyang Lin, et al.
Published: (2024-02-01)

The variable manifestations of disease in pyruvate kinase deficiency and their management
by: Hanny Al-Samkari, et al.
Published: (2020-03-01)

Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease
by: Sara El Hoss, et al.
Published: (2020-08-01)

High Resolution Crystal Structure of the Pyruvate Kinase Tetramer in Complex with the Allosteric Activator Mitapivat/AG-348
by: Xiao Han, et al.
Published: (2024-05-01)

A mechanism of ineffective erythropoiesis in β-thalassemia/Hb E disease
by: Pathrapol Lithanatudom, et al.
Published: (2010-05-01)

Reduced GATA1 levels are associated with ineffective erythropoiesis in sickle cell anemia
by: Sara El Hoss, et al.
Published: (2024-12-01)

AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes
by: Minke A.E. Rab, et al.
Published: (2020-01-01)

The correlation between ineffective erythropoiesis biomarkers and development of extramedullary hematopoiesis in patients with thalassemia
by: Siriyakorn Chansai, et al.
Published: (2022-06-01)

Congenital dyserythropoietic anemia type II and ineffective erythropoiesis: challenges in diagnosis and management
by: Imo J. Akpan, et al.
Published: (2024-07-01)

P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
by: Myrthe van Dijk, et al.
Published: (2023-08-01)

S273: EVIDENCE OF NONINFERIORITY OF MITAPIVAT VERSUS SPLENECTOMY IN MURINE HEREDITARY SPHEROCYTOSIS
by: A. Matte’, et al.
Published: (2022-06-01)

Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease
by: Angelo D’Alessandro, et al.
Published: (2024-03-01)

SF3B1 deficiency impairs human erythropoiesis via activation of p53 pathway: implications for understanding of ineffective erythropoiesis in MDS
by: Yumin Huang, et al.
Published: (2018-02-01)

Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study
by: Eduard J. van Beers, et al.
Published: (2019-02-01)

5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
by: M.J. van Dijk, et al.
Published: (2023-04-01)

PB2247: PHARMACOKINETIC MODELING AND SIMULATION TO SUPPORT MITAPIVAT DOSE SELECTION USED IN PEDIATRIC PHASE III STUDIES
by: O. Yin, et al.
Published: (2022-06-01)

P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
by: M. J. van Dijk, et al.
Published: (2022-06-01)